

Psilocybin Clinical Trials and Projects

#	Study Phase or Design	End Year	Outcome	Trial Status	Location	Sponsor	n	Masking	Control	Trial Identifier or DOI
1	Phase 2b	2021	Depression - Treatment-Resistant Depression	Complete	US, multi-site; CA, Ontario; CZ; DK; DE; IL; NL; PT; ES; UK	COMPASS Pathways	233	Quadruple	Parallel	NCT03775200
2	Phase 2	2022	Eating Disorder - Anorexia Nervosa	Complete	US, California	University of California	16	Open	None	NCT04661514
3		2022	Depression - Major Depressive Disorder	Complete	CH	University of Zurich	55	Quadruple	Placebo	NCT03715127
4		2021	Depression - Treatment-Resistant Depression	Complete	US, California; IE	COMPASS Pathways	19	Open	None	NCT04739865
5		2021	Addiction - alcohol	Complete	US, New York	NYU Langone Health	135	Quadruple	Active	NCT02061293
6		2020	Mechanism - cognitive enhancement	Complete	NL	University Maastricht	60	Double	Placebo	NTR6505
7		2020	Depression - Major Depressive Disorder	Complete	UK	Imperial College London	59	Double	Parallel	NCT03429075
8		2020	Depression - Major Depressive Disorder	Complete	US, Maryland	Johns Hopkins University	27	Single	Comparison	NCT03181529
9		2016	Cancer - anxiety, depression	Complete	US, Maryland	Johns Hopkins University	56	Quadruple	Parallel	NCT00465595
10	Phase 1b	2018	Mechanism - emotional brain functioning	Complete	US, Maryland	Johns Hopkins University	13	Open	None	NCT02971605
11		2008	Cancer - pain, anxiety, depression	Complete	US, California	Harber-UCLA Medical Center	12	Quadruple	Placebo	NCT00302744
12	Phase 1	2020	Mechanism - antidepressant comparison	Complete	CH	University Hospital, Basel	27	Triple	Placebo	NCT03912974
13		2020	Mechanism - religious leaders	Complete	US, New York	NYU Langone Health	12	Open	None	NCT02421263
14		2019	AIDS Survivors - demoralisation	Complete	US, California	Joshua Woolley, MD	30	Open	None	NCT02950467
15		2019	Mechanism - brain functioning	Complete	CH	University Hospital, Basel	40	Double	Placebo	NCT02145091
16		2018	Mechanism - brain functioning	Complete	CH	University of Zurich	140	Double	Placebo	NCT03736980
17		2015	Mechanism - pharmacokinetics	Complete	US, Wisconsin	University of Wisconsin	12	Open	None	NCT02163707
18		2014	Mechanism - brain functioning	Complete	US, Maryland	Johns Hopkins University	10	Open	None	NCT01988311
19		2014	Mechanism - spiritual practice	Complete	CH	University Hospital, Basel	75	Quadruple	Parallel	NCT00802282
20		2006	Mechanism - pharmacokinetics	Complete	US, Maryland	Johns Hopkins University	36	Double	Active	10.1007/s00213-006-0457-5
21	Phase 0	2021	Microdose - cognitive enhancement	Complete	AR	National Council of Scientific and Technical Research	34	Double	Placebo	NCT05160220
22		2021	Mechanism - pharmacoinaging	Complete	CH	University of Zurich	25	Quadruple	Placebo	NCT03853577
23		2021	Mechanism - LSD comparison	Complete	CH	University Hospital, Basel	28	Quadruple	Placebo	NCT03604744
24		2018*	Microdose - cognitive enhancement	Complete	NL	Psychedelic Society of the Netherlands	38	Open	None	10.1007/s00213-018-5049-7
25		2018	Cancer - anxiety, depression	Complete	US, New York	NYU Langone Health	29	Quadruple	Placebo	NCT00957359
26	Observational	2020	Follow up - anxiety in cancer patients	Complete	US, New York	NYU Langone Health	15	n/a	n/a	10.1177/0269881119897615
27		2016	Follow up - tobacco addiction	Complete	US, Maryland	Johns Hopkins University	15	n/a	n/a	10.3109/00952990.2016.1170135
28		2008	Follow up - safety mechanism	Complete	US, Maryland	Johns Hopkins University	36	n/a	n/a	10.1177/0269881108094300
29	Phase 2b	2027	Cancer - anxiety, depression, existential distress	Not started	US, New York	NYU Langone Health	300	Double	Placebo	NCT05398484
30		2023	Depression - Treatment-Resistant Depression	Active	CA, Ontario	Brain and Cognition Discovery Foundation	30	Open	None	NCT05029466
31		2022	Cancer - Major Depressive Disorder	Active	US, Maryland	Maryland Oncology Haematology PA	30	Open	None	NCT04593563
32		2022	Body Dysmorphic Disorder	Active	US, New York	New York State Psychiatric Institute	12	Open	None	NCT04656301
33		2022	Addiction - alcohol	Active	US, California	Keith Heinzerling	20	Open	Comparison	NCT04410913

Psilocybin Clinical Trials and Projects

#	Study Phase or Design	End Year	Outcome	Trial Status	Location	Sponsor	n	Masking	Control	Trial Identifier or DOI
34	Phase 2	2022	Depression - Major Depressive Disorder	Active	US, multi-site	Usona Institute	100	Triple	Plaebo	NCT03866174
35		n.d.	Headache - chronic cluster	Active	DK	NeuroPharm	20	Open	None	EUCTR2018-003382-35-DK
36		n.d.	Eating Disorder - Anorexia Nervosa	Active	UK	Imperial College London	20	Single	None	EUCTR2019-004054-28-GB
37		n.d.	Depression - Major Depressive Disorder	Active	SE	SLSO	30	Double	Placebo	EUCTR2020-002790-94-SE
38		n.d.	Depression - Treatment Resistant Depression	Active	DE	Central Institute of Mental Health	144	Double	Parallel	EUCTR2019-003984-24-DE
39		n.d.	Addiction - alcohol	Active	DK	Psychiatric Centre Copenhagen	100	Double	Placebo	EUCTR2020-000829-55-DK
40		n.d.	Cancer - depression	Active	CZ	Národní ústav Duševního Zdraví	60	Double	Parallel	EUCTR2020-00-5037-32-CZ
41		n.d.	Microdose - Parkinson's Disease	Active	NL	Maastricht University	34	Double	Placebo	EUCTR2021-0000-41-40-NK
42		2026	Depression - Major Depressive Disorder; Addiction - alcohol	Recruiting	US, Maryland	Johns Hopkins University	90	Quadruple	Placebo	NCT04620759
43		2025	Depression - Treatment-Resistant Depression	Recruiting	CZ	National Institute of Mental Health	60	Quadruple	Active	NCT05383313
44		2025	Eating Disorder - Binge Eating	Recruiting	US, Florida	TRYP Therapeutics	10	Open	None	NCT05035927
45		2024	Hospice Care - demoralisation	Recruiting	US, Massachusetts	Yvan Beaussant	15	Open	None	NCT04950608
46		2024	Treatment-Resistant Depression - chronic suicidal ideation	Recruiting	US, Maryland	Shepphard Pratt Helath System	20	Open	None	NCT05220410
47		2024	Depression - Treatment-Resistant Depression	Recruiting	DE	Central Institute of Mental Health	144	Triple	Placebo	NCT04670081
48		2023	Anxiety - Generalised Anxiety Disorder	Recruiting	AU, Victoria	Monash University	72	Quadruple	Parallel	ACTRN12621001358831
49		2023	Depression - Treatment-Resistant Depression	Recruiting	AU, Victoria	Swinburne University	15	Open	None	ACTRN12621001097831
50		2023	Palliative Care - depression, anxiety	Recruiting	AU, Victoria	St Vincent's Hospital Melbourne	40	Quadruple	Placebo	ACTRN12619001225101
51		2023	Post-Traumatic Stress Disorder	Recruiting	US, New York; UK	COMPASS Pathways	20	Open	None	NCT05312151
52		2023	Bipolar 2 Disorder - depression	Recruiting	US, California	University of California	14	Open	None	NCT05065294
53		2023	Post-Traumatic Stress Disorder	Recruiting	CA, Nova Scotia	Halucenex Life Sciences	20	Open	None	NCT05243329
54		2023	Eating Disorder - Anorexia Nervosa	Recruiting	US, multi-site; UK	COMPASS Pathways	60	Quadruple	Active	NCT05481736
55		2023	Addiction - calcohol	Recruiting	CH	University of Zurich	60	Triple	Placebo	NCT04141501
56		2023	Depression - Treatment-Resistant Depression	Recruiting	UK	King's College London	60	Quadruple	Placebo	NCT04959253
57		2022	Depression - Major Depressive Disorder	Recruiting	SE	Northern Stockholm Psychiatry	30	Quadruple	Placebo	NCT04630964
58		2022	Depression - Treatment-Resistant Depression	Recruiting	US, Maryland	Shepphard Pratt Helath System	15	Open	None	NCT04433758
59		2022	Addiction - cocaine	Recruiting	US, Alabama	University of Alabama	40	Quadruple	Active	NCT02037126
60		2022	Bipolar 2 Disorder - Treatment-Resistant Depression	Recruiting	US, Maryland	Shepphard Pratt Helath System	12	Open	None	NCT04433845
61		2022	Parkinson's Disease - depression, anxiety	Recruiting	US, California	Joshua Woolley, MD	10	Open	None	NCT04932434
62		2026	Palliative Care - demoralisation	Not started	US, California	Charles S. Grob, MD	100	Triple	Active	NCT05403086
63		2025	Addiction - alcohol	Not started	DK	Anders Fink-Jensen, MD	90	Quadruple	Placebo	NCT05416229
64		2024	Pain - Fibromyalgia	Not started	US, Florida	TRYP Therapeutics	20	Open	None	NCT05128162
65		2024	Depression - Treatment-Resistant Major Depressive Disorder	Not started	US, Massachusetts	Massachusetts General Hospital	20	Open	None	NCT05381974
66		2024	Addiction - opioids	Not started	US, Maryland	Johns Hopkins University	92	Quadruple	Placebo	NCT05242029
67		2024	Addiction - tobacco	Not started	US, Maryland	Johns Hopkins University	66	Quadruple	Placebo	NCT05452772

Psilocybin Clinical Trials and Projects

#	Study Phase or Design	End Year	Outcome	Trial Status	Location	Sponsor	n	Masking	Control	Trial Identifier or DOI
68		2023	Microdose - persistant depressive disorder	Not started	CA, Ontario	Rotem Petranker	50	Triple	Placebo	NCT05259943
69		2023	Depression - Major Depressive Disorder; Borderline Personality Disorder	Not started	US, Illinois	University of Chicago	10	Open	None	NCT05399498
70		2023	Addiction - alcohol	Not started	US, Iowa	Peggy C. Nopoulos, MD	20	Open	None	NCT05421065
71		2023	Addiction - alcohol	Not started	DK	Anders Fink-Jensen, MD	10	Open	None	NCT04718792
72		n.d.	Depression - Treatment-Resistant Depression	Not started	UK	Imperial College London	12	Open	None	EUCTR2013-003196-35-GB
73		n.d.	Depression - Major Depressive Disorder	Not started	UK	Imperial College London	50	Double	Placebo	EUCTR2017-000219-18-GB
74	Phase 1b	2024	Mechanism - pharmacoinaging	Active	US, Maryland	Johns Hopkins University	6	Quadruple	Placebo	NCT05301608
75		2025	Addiction - methamphetamine	Recruiting	US, Washington	Portland VA Research Foundation	30	Single	Active	NCT04982796
76		2023	Depression - burnout	Recruiting	US, Washington	University of Washington	30	Triple	Placebo	NCT05163496
77		2023	Eating Disorder - Anorexia Nervosa	Recruiting	UK	Imperial College London	20	Open	None	NCT04505189
78		2022	Headache - short-lasting unilateral neuralgiform	Recruiting	UK	Beckley Psytech Limited	12	Open	None	NCT04905121
79		2025	Obsessive Compulsive Disorder	Not started	IL	Beersheva Mental Health Centre	15	Open	None	NCT04882839
80	Phase 1	2024	Microdose - anxiety	Not started	CA, multi-site	Ottawa Hospital Research Institute	40	Open	None	NCT04754061
81		2024	Pain - Chronic lower back	Not started	US, California	Joshua Woolley, MD	30	Quadruple	Parallel	NCT05351541
82		2023	Depression - Major Depressive Disorder	Active	US, Connecticut	Yale University	18	Double	Placebo	NCT03554174
83		2023	Addiction - tobacco	Active	US, Maryland	Johns Hopkins University	95	Open	Comparison	NCT01943994
84		2023	Mechanism - religious leaders	Active	US, Maryland	Johns Hopkins University	20	Open	None	NCT02243813
85		2023	Addiction - opioids	Active	US, Wisconsin	University of Wisconsin	10	Open	None	NCT04161066
86		2023	Headache - cluster	Active	US, Connecticut	Yale University	24	Triple	Placebo	NCT02981173
87		2022	Headache - migraine	Active	US, Connecticut	Yale University	24	Double	Placebo	NCT03341689
88		2022	Eating Disorder - Anorexia Nervosa	Active	US, Maryland	Johns Hopkins University	18	Open	None	NCT04052568
89		2022	Obsessive Compulsive Disorder	Active	US, Arizona	University of Arizona	15	Quadruple	Placebo	NCT03300947
90		2022	Mechanism - LSD, mescaline comparison	Active	CH	University Hospital, Basel	30	Quadruple	Placebo	NCT04227756
91		2027	Mechanism - pharmacoinaging	Recruiting	DK	Gitte Moos Knudsen	200	Single	Active	NCT03289949
92		2024	Mechanism - pharmacokinetics	Recruiting	US, California	University of California	20	Triple	Parallel	NCT05317689
93		2024	Mechanism - neurobiology	Recruiting	US, Minnesota	University of Minnesota	75	Triple	Placebo	NCT04424225
94		2024	Headache - migraine	Recruiting	US, Connecticut	Yale University	24	Quadruple	Placebo	NCT04218539
95		2024	Post-Treatment Lyme Disease	Recruiting	US, Meryland	Johns Hopkins University	20	Open	None	NCT05305105
96		2023	Mechanism - supratherapeutic dose	Recruiting	US, Kansas	Usona Institute	36	Triple	Active	NCT05478278
97		2023	Obsessive Compulsive Disorder	Recruiting	US, Connecticut	Yale University	30	Quadruple	Plaebro	NCT03356483
98		2023	Mechanism - pharmacoinaging	Recruiting	AU, Victoria	Monash University	60	Open	None	ACTRN12621001375842
99		2023	Headache - post-traumatic	Recruiting	US, Connecticut	Yale University	24	Double	Comparison	NCT03806985
100		2023	Mechanism - pharmacoinaging	Recruiting	AU, Victoria	Monash University	60	Open	Parallel	ACTRN12621001375842
101		2023	Mechanism - Major Depressive Disorder	Recruiting	US, Wisconsin	University of Wisconsin	12	Open	None	NCT04842045
102		2023	Pallitive - pain, anxiety, depression	Recruiting	US, Georgia	Emory University	10	Open	None	NCT05506982
103		2026	Obsessive Compulsive Disorder	Not started	US, Connecticut	Yale University	30	Single	Active	NCT05370911

Psilocybin Clinical Trials and Projects

#	Study Phase or Design	End Year	Outcome	Trial Status	Location	Sponsor	n	Masking	Control	Trial Identifier or DOI
104		2025	Mechanism - pharmacoinaging	Not started	US, California	University of California	80	Double	Comparison	NCT05265546
105		2025	Addiction - methamphetamine	Not started	AU, New South Wales	St Vincent's Hospital Darlinghurst	15	Open	None	ACTRN12622000463774
106		2025	Cancer - psychological distress	Not started	US, Nebraska	Lou Lukas	24	Open	None	NCT05220046
107		2024	Mechanism - MDMA, 2C-B comparison	Not started	CH	University Hospital, Basel	24	Triple	Placebo	NCT05523401
108		2024	Microdose - trauma	Not started	US, Montana	NWTraumatherapies	30	Quadruple	Parallel	NCT05042466
109		2024	Functional Neurological Disorder	Not started	AU, Victoria	Austin Health	22	Open	None	ACTRN12621000560897
110		2024	Functional Neurological Disorder	Not started	AU, Victoria	Austin Health	12	Open	None	ACTRN12621000578808
111		2023	Addiction - methamphetamine	Not started	US, Wisconsin	University of Wisconsin	12	Open	None	NCT05322954
112		2023	Mechanism - pharmacokinetics	Not started	US, Wisconsin	University of Wisconsin	8	Open	None	NCT05467761
113		2023	Pain - phantom limb	Not started	US, California	University of California	20	Triple	Placebo	NCT05224336
114		2022	Cancer - depression, anxiety	Active	US, Utah	University of Utah	12	Open	None	NCT04522804
115	Phase 0	2022	Mechanism - pharmacoinaging	Active	US, Missouri	Washington University	25	Single	Control	NCT04501653
116		n.d.	Schizophrenia - pharmacoinaging	Active	CZ	National Institute of Mental Health	40	Open	None	EUCTR2012-004579-37-CZ
117		2023	Alzheimer's Disease - depression	Recruiting	US, Maryland	Johns Hopkins University	20	Open	None	NCT04123314
118		2026	Depression - Major Depressive Disorder	Not started	US, California	University of California	30	Open	None	NCT05227612
118		2024	Pain - Fibromyalgia	Not started	US, Alabama	University of Alabama	30	Quadruple	Placebo	NCT05068791
119		2023	Microdose - demoralisation	Not started	US, Alabama	University of Alabama	60	Quadruple	Placebo	NCT05227742
120		2022	Microdose - general enhancement	Not started	CA, Alberta	Optimi Health Corporation	20	Quadruple	Placebo	NCT05252598
121	Observational	2023	Follow up - Major Depressive Disorder	Recruiting	US, Florida	Usona Institute	100	n/a	n/a	NCT04353921
122		2022	Follow up - Treatment-Resistant Depression	Recruiting	US, multi-site; CA, Ontario; CZ; DK; DE; IL; NL; PT; ES; UK	COMPASS Pathways	150	n/a	n/a	NCT04519957